KROS•benzinga•
Keros Therapeutics Announces Additional Update On The Phase 2 TROPOS Trial: Company Says It Voluntarily Halted All Dosing In The TROPOS Trial Based On The Ongoing Safety Review Due To New Observations Of Pericardial Effusion Adverse Events
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 15, 2025 by benzinga